★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Reckitt Benckiser Group plc (RKT) Moat Analysis
Reckitt Benckiser Group plc
RKT · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Reckitt is a UK consumer health and hygiene company refocused on Core Reckitt, while treating Mead Johnson Nutrition as non-core. H1 2026 Core revenue was GBP 5.110 billion and adjusted operating profit was GBP 1.266 billion. Powerbrand trust is the clearest moat, but only 45% of top Category Market Units held or gained share. MJN revenue was GBP 1.066 billion and adjusted operating profit was GBP 191 million. Medical recommendation supports its infant-nutrition brands, but North American share loss, declining volume, and unresolved NEC litigation reduce moat strength. The first federal NEC bellwether trial began on August 17 and remained unresolved. Reckitt says a possible outflow cannot be estimated reliably and may be significant. Promotions, private label, litigation, recalls, and category softness are the main risks.
Primary segment
Core Reckitt
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 6 tags
Updated 2026-08-23
Segments
Core Reckitt
Branded consumer health and hygiene (self-care OTC, intimate wellness, germ protection, household care)
Revenue
82.7%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Mead Johnson Nutrition
Infant formula and specialized child nutrition
Revenue
17.3%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Core Reckitt
Branded consumer health and hygiene (self-care OTC, intimate wellness, germ protection, household care)
Revenue share normalizes H1 2026 Core Reckitt net revenue of GBP 5,110m against Core Reckitt plus Mead Johnson Nutrition revenue of GBP 6,176m. Operating-profit share uses Core adjusted operating profit of GBP 1,266m against GBP 1,457m for Core plus MJN. Both calculations exclude GBP 235m of temporary Vestacy transitional-services revenue and its GBP 12m profit, which arise from the Essential Home separation rather than an enduring product market. Source: https://eu-assets.contentstack.com/v3/assets/blt93c8bc7a598af9f0/blt95cf941f3c07d9ff/6a6987914fedb5b67f067a59/Reckitt_RNS_H1_2026_Final_Signed.pdf
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Trusted global 'Powerbrands' in health and hygiene support repeat purchase and premium positioning.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Private label and value-brand trading down
- Brand damage from quality/safety issues
- Feature parity reducing differentiation (e.g., cleaners, OTC remedies)
Leading indicators
- Price/mix vs volume trend by quarter
- Brand equity investment (BEI) as % of net revenue
- Market share trend in top Category Market Units (CMUs)
Counterarguments
- Many categories have low switching costs; promotion can move share quickly
- Large rivals (P&G, Unilever) can match marketing spend and shelf presence
Mead Johnson Nutrition
Infant formula and specialized child nutrition
Revenue share normalizes H1 2026 Mead Johnson Nutrition revenue of GBP 1,066m against Core plus MJN revenue of GBP 6,176m. Operating-profit share uses MJN adjusted operating profit of GBP 191m against GBP 1,457m for Core plus MJN. MJN volume fell 3.9%, price/mix rose 5.9%, and adjusted operating margin fell 240 basis points to 17.9%. Reckitt describes MJN as non-core and continues to defend US NEC litigation. Source: https://eu-assets.contentstack.com/v3/assets/blt93c8bc7a598af9f0/blt95cf941f3c07d9ff/6a6987914fedb5b67f067a59/Reckitt_RNS_H1_2026_Final_Signed.pdf
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Enfamil's brand equity and medical recommendation underpin demand in infant formula despite category scrutiny.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Litigation outcomes and reputational damage
- Product recalls or quality incidents
- Share loss to private label or competitors post-supply normalization
Leading indicators
- Non-WIC and total value market share trends
- Regulatory inspection outcomes and remediation costs
- Litigation developments and settlement reserves
Counterarguments
- Medical recommendation effects can be diluted by aggressive competitor promotion and pricing
- Trust can unwind quickly after safety events in infant categories
Evidence
Our Business is centred on 11 Powerbrands
Annual report frames Core Reckitt around a concentrated set of trusted brands across health and hygiene categories.
The strength of our Powerbrands and strong consumer response to our recent innovations underpin these results
Current results attribute performance partly to Powerbrands and innovation, supporting continued consumer pull.
45% of Core Reckitt Top CMUs are holding or gaining share
Current share performance is mixed and below the company's 60% target, limiting the moat score despite brand strength.
Strong paediatric recommendation data underpinned its leadership
Annual report supports a recommendation-led moat in specialty infant nutrition, especially Nutramigen.
Market share gains across International markets driven by enhanced execution were partially offset by share losses in North America
Current evidence is mixed: international execution improved, while the largest market suffered competitive and supply-related share loss.
Risks & Indicators
Erosion risks
- Private label and value-brand trading down
- Brand damage from quality/safety issues
- Feature parity reducing differentiation (e.g., cleaners, OTC remedies)
- Litigation outcomes and reputational damage
- Product recalls or quality incidents
- Share loss to private label or competitors post-supply normalization
Leading indicators
- Price/mix vs volume trend by quarter
- Brand equity investment (BEI) as % of net revenue
- Market share trend in top Category Market Units (CMUs)
- Non-WIC and total value market share trends
- Regulatory inspection outcomes and remediation costs
- Litigation developments and settlement reserves
Research RKT elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.